News and Announcements
Crowd Mobile and SmartTrans Launch New Product Bobo In China
- Published February 21, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Crowd Mobile Limited (ASX: CM8) is pleased to announce it has successfully launched its pilot product Bobo in China in partnership with SmartTrans Holdings Limited (ASX:SMA).
BACKGROUND:
- Crowd Mobile and SmartTrans signed a Letter of Intent on August 1, 2016 to utilise SmartTran’s established multi-currency online payment platform SmartPay in China.
- Crowd Mobile will leverage SmartTrans’ online payments platform to launch its product offering a quick and easy way to monetise the Chinese market.
KEY TAKAWAYS:
- Crowd Mobile and SmartTrans successfully launch pilot product Bobo in China.
- Bobo is an entertainment/infotainment product targeting the millennial demographic.
- Bobo pilot launch follows completion of technical testing and integration.
- Modest revenues expected initially while China remains a large consumer market opportunity.
SmartTrans’ Chief Executive Officer, Bryan Carr commented: “We are pleased to be partnering with Crowd Mobile on the deployment of BoBo into China. Our well established telco and e-commerce partnerships will make BoBo available to a very large and engaged mobile-enabled consumer base.
“We will initially deploy BoBo to consumers in Sichuan Province through a pilot program with China Mobile with committed marketing dollars from Crowd Mobile. The result of this pilot will then determine the roll-out of BoBo into SmartTrans’ much larger China footprint which, with the combination of telco billing through China Mobile and China Telecom and the payment processing capabilities through AliPay, WeChat Pay and UnionPay, reaches across the whole of China.”
Crowd Mobile’s Chief Executive Officer, Domenic Carosa commented: “Crowd Mobile has been committed to entering China and the pilot launch of our new BoBo product is a milestone for the Company. We plan to build on the global success of our Question and Answer (Q&A) division, and expect BoBo will be well received in China.
“Our partnership with SmartTrans offers both companies an opportunity to generate significant revenues from one of the fastest growing mobile markets in the world. Chinese consumers are known to embrace mobile infotainment and entertainment products. As BoBo is focused on the young millennial demographic, we are excited about the opportunity that awaits. “SmartTrans’ established online payments platform, SmartPay, will facilitate smooth and easy integration with Crowd Mobile and we look forward to working together and communicating developments to our shareholders.”
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
